从抗真菌药到抗癌斗士:伊曲康唑作为耐药性前列腺癌的多面候选药物
本综述汇总了伊曲康唑(ITZ)在前列腺癌及其他恶性肿瘤中的临床前机制数据与临床经验,评估其靶向的信号通路、临床转化障碍及生物标志物驱动的联合治疗机会。ITZ可调节Hedgehog/GLI、PI3K/AKT/mTOR和Wnt/β-catenin等通路及药物外排转运体,临床前研究显示其可逆转ABCB1介导的多西他赛耐药,但在mCRPC中临床活性有限,存在转化脱节。
要点
- ITZ是多效抗癌化合物,可调节Hedgehog/GLI、PI3K/AKT/mTOR、Wnt/β-catenin通路及药物外排转运体。
- 临床前研究显示ITZ可逆转ABCB1介导的多西他赛耐药、抑制Hedgehog/GLI1信号及癌细胞增殖和侵袭。
- ITZ在mCRPC中临床活性有限,持久缓解少,受药代动力学、剂量限制性毒性和缺乏验证性预测生物标志物制约。
核心结论
- ITZ是mCRPC合理设计、生物标志物分层联合方案中的潜在辅助策略。
- 目标人群包括PTEN缺失肿瘤、ABCB1过表达肿瘤或AR通路抑制剂治疗后进展的患者。
研究设计与样本
- 本综述综合了伊曲康唑在 prostate cancer 及其他恶性肿瘤中的临床前机制数据和临床经验。
主要发现
- ITZ调节Hedgehog/GLI、PI3K/AKT/mTOR和Wnt/β-catenin信号通路以及药物外排转运体。
- 临床前研究显示ITZ逆转ABCB1介导的多西他赛耐药、抑制Hedgehog/GLI1信号并抑制癌细胞增殖和侵袭。
- ITZ在mCRPC中临床活性有限,持久缓解少,存在转化脱节。
- 新兴证据提示ITZ可能通过调节肿瘤微环境与免疫检查点抑制剂产生协同作用,但在前列腺癌中尚未探索。
关键数值与推荐
- 临床推进需要药理学优化、患者分层生物标志物(GLI1/PTCH1、PTEN状态、ABCB1表达)的开发与验证,以及与靶向互补耐药通路的治疗整合。
临床怎么用
- ITZ可作为mCRPC患者 rationally designed、biomarker-stratified 联合方案中的辅助策略。
- 目标人群包括PTEN缺失肿瘤(Hh/GLI和PI3K/AKT信号升高)、ABCB1过表达肿瘤(紫杉烷耐药)或AR通路抑制剂治疗后进展的患者。
局限性
- ITZ的临床推进受药代动力学挑战、剂量限制性毒性及缺乏验证性预测生物标志物制约。
- ITZ与免疫检查点抑制剂的协同作用在前列腺癌中尚未探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease state with limited durable responses to existing therapies, including taxane-based chemotherapy. Resistance mechanisms are multifactorial and incompletely addressed by current treatments. Drug repurposing offers an accelerated pathway for the development of novel therapeutic strategies in treatment-resistant disease. METHODS: This review synthesizes preclinical mechanistic data and clinical experience with itraconazole (ITZ), a clinically approved triazole antifungal, across prostate cancer and other malignancies. We evaluate the signaling pathways targeted by ITZ, barriers to its clinical translation, and opportunities for biomarker-driven combination therapy. RESULTS: ITZ functions as a pleiotropic anticancer compound that modulates multiple pathways implicated in prostate cancer progression and therapeutic resistance, including Hedgehog/GLI, PI3K/AKT/mTOR, and Wnt/β-catenin signaling, as well as drug efflux transporters. Preclinical studies demonstrate that ITZ reverses ABCB1-mediated docetaxel resistance, suppresses Hedgehog/GLI1 signaling, and inhibits cancer cell proliferation and invasion. Despite compelling mechanistic rationale, clinical activity in mCRPC has been modest, with limited durable responses, underscoring a translational disconnect. Advancement of ITZ into clinical practice is constrained by pharmacokinetic challenges, dose-limiting toxicities, and the lack of validated predictive biomarkers to identify responsive patient subsets. Emerging evidence further suggests potential synergy with immune checkpoint inhibitors through tumor microenvironment modulation, though this remains unexplored in prostate cancer. CONCLUSIONS: ITZ represents a potential adjunctive strategy to standard therapies within rationally designed, biomarker-stratified combination regimens for mCRPC. Target populations include patients with PTEN-null tumors (elevated Hh/GLI and PI3K/AKT signaling), ABCB1-overexpressing tumors (taxane resistance), or those progressing after AR pathway inhibitor therapy. Clinical advancement will require pharmacological optimization, development and validation of patient stratification biomarkers (GLI1/PTCH1, PTEN status, ABCB1 expression), and integration with therapies targeting complementary resistance pathways.
引用
- Souza LO, Papoutsi DG, Moreira JMA, et al. From fungus fighter to cancer slayer: itraconazole as a multifaceted candidate for drug-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2026. PMID: 42562963. doi:10.1038/s41391-026-01142-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。